Literature DB >> 6125279

Effect of radioiodine on stimulatory activity of Graves' immunoglobulins.

S Atkinson, A M McGregor, P Kendall-Taylor, M M Peterson, B R Smith.   

Abstract

The effects of 131I therapy on the activity of thyroid stimulating antibody (TSAb) and thyrotrophin binding inhibiting immunoglobulin (TBII) in nineteen patients with Graves' disease have been studied. Prior to 131I administration TSAb was detected in 84%, and TBII in 68% of patients. Following 131I administration TSAb and TBII were detectable in 100% of patients. The elevation 3 months after treatment of the means of both the TSAb and TBII indices for the group of nineteen patients was highly significant compared with pre treatment values. All the patients went into remission during the course of the study and the TSAb index declined in all patients, becoming undetectable in eleven; TBII also declined in most patients but remained detectable in thirteen. The study furthermore afforded the opportunity for a direct comparison of binding with stimulatory activity. These results show that after 131I therapy for Graves' hyperthyroidism there is a transient increase in TSAb as well as TBII, followed by a decline, and that the measurement of binding and stimulatory activities are in good general agreement.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125279     DOI: 10.1111/j.1365-2265.1982.tb03170.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Greater Efficacy of Total Thyroidectomy versus Radioiodine Therapy on Hyperthyroidism and Thyroid-Stimulating Immunoglobulin Levels in Patients with Graves' Disease Previously Treated with Antithyroid Drugs.

Authors:  Shakeel Kautbally; Orsalia Alexopoulou; Chantal Daumerie; François Jamar; Michel Mourad; Dominique Maiter
Journal:  Eur Thyroid J       Date:  2012-06-20

2.  Early prediction of hypothyroidism following 131I treatment for Graves' disease.

Authors:  R Wilson; J H McKillop; E Black; C Jenkins; J A Thomson
Journal:  Eur J Nucl Med       Date:  1988

3.  Relationship between thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins years after administration of radioiodine for Graves' disease: retrospective clinical survey.

Authors:  K Yoshida; Y Aizawa; N Kaise; H Fukazawa; Y Kiso; N Sayama; K Mori; H Hori; K Abe
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

4.  Thyroid-stimulating antibodies in patients with long-term remission of Graves' hyperthyroidism.

Authors:  R Hörmann; A Hobelsberger; B Saller; K Mann
Journal:  Klin Wochenschr       Date:  1986-10-31

5.  The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease.

Authors:  Ola Lindgren; Pernilla Asp; Anna Sundlöv; Jan Tennvall; Bushra Shahida; Tereza Planck; Peter Åsman; Mikael Lantz
Journal:  Eur Thyroid J       Date:  2019-01-03

Review 6.  Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance.

Authors:  Ines Bucci; Cesidio Giuliani; Giorgio Napolitano
Journal:  Front Endocrinol (Lausanne)       Date:  2017-06-30       Impact factor: 5.555

7.  The effect of radioiodine treatment on the characteristics of TRAb in Graves' disease.

Authors:  Ya Fang; Wen-Hua Du; Cao-Xu Zhang; Shuang-Xia Zhao; Huai-Dong Song; Guan-Qi Gao; Mei Dong
Journal:  BMC Endocr Disord       Date:  2021-11-30       Impact factor: 2.763

8.  Radioiodine thyroid ablation in graves' hyperthyroidism: merits and pitfalls.

Authors:  J F Nwatsock; D Taieb; L Tessonnier; J Mancini; F Dong-A-Zok; O Mundler
Journal:  World J Nucl Med       Date:  2012-01

9.  Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.

Authors:  B Y Cho; Y K Shong; J K Chung; M C Lee; H K Lee; C S Koh; H K Min
Journal:  Korean J Intern Med       Date:  1990-01       Impact factor: 2.884

Review 10.  The Clinical Value and Variation of Antithyroid Antibodies during Pregnancy.

Authors:  Chuyu Li; Jing Zhou; Zengshu Huang; Xinyao Pan; Wingting Leung; Lijia Chen; Yanzhi Zhang; Lan Wang; Yizhen Sima; Hans-Jürgen Gober; Na Zhang; Xuemin Qiu; Lisha Li; Liang Guan; Ling Wang
Journal:  Dis Markers       Date:  2020-10-21       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.